teplizumab
Jun 12, 2019
Teplizumab delays the progression of Type 1 Diabetes
The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high risk for type 1 diabetes. According to recent Phase II clinical trials, in experimental immunotherapy conducted, the drug has been able to delay the onset of disease for the first tim...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
